Skip to content

Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment

Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03548480
Acronym
BALPWS
Enrollment
39
Registered
2018-06-07
Start date
2018-01-01
Completion date
2019-01-31
Last updated
2020-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prader-Willi Syndrome

Brief summary

The gut microbiome has recently emerged as a major contributor to obesity, systemic inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in the gut-brain axis, regulating a broad range of central nervous system processes, from satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being actively investigated as a therapeutic strategy for a wide array of diseases, including obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal models and human subjects, improving body composition and metabolic health, and reducing energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation, the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here, the investigators will test this hypothesis by performing a randomized double-blinded placebo-controlled crossover clinical study to assess the effects of BAL supplementation on an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as well as biological samples will be obtained at the beginning of the study, and after each of the study periods, with a total of four time-points. Specifically, the investigators will determine body composition by DXA analysis; metabolic health by assessing glucose and lipid metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by applying parental-rated validated questionnaires.

Interventions

DIETARY_SUPPLEMENTPlacebo

Intervention with a daily dose of placebo

DIETARY_SUPPLEMENTProbiotic

Intervention with a daily dose of probiotic

Sponsors

Fundació Sant Joan de Déu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 19 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with Prader-Willi Syndrome with genetic confirmation * On a stable diet and medication regimen for at least the last two months before enrollment

Exclusion criteria

* Current enrollment in or discontinuation within the last 30 days from a clinical trial * Presence of other medical problems that would preclude study participation * Patients with a history of bariatric surgery * Unsuitable for inclusion in the study in the opinion of the investigator

Design outcomes

Primary

MeasureTime frameDescription
Change in percent body fat3 monthsMeasured by DXA scan

Secondary

MeasureTime frameDescription
Change in glucose metabolic parameters (glucose, insulin, HbA1c)3 monthsBlood test after overnight fasting
Change in circulating cytokine levels3 monthsQuantified in plasma samples
Change in hyperphagia3 monthsMeasured by validated questionnaire (HQ-CT)
Change in thermoregulation3 monthsMeasured by thermal imaging
Change in lipid profile (triglyceride, cholesterol)3 monthsBlood test after overnight fasting

Other

MeasureTime frameDescription
Change in intestinal microbiome3 monthsDNA isolated from fecal samples will be analyzed by sequencing.
Change in urine metabolome3 monthsLiquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of urine samples
Change in plasma metabolome3 monthsLiquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026